FOXD1 and cancer: Accumulating evidence has demonstrated that FOXD1 is associated with tumorigenesis and cancer progression, such as therapeutic resistance and cancer metastasis, and serves as a prognostic biomarker and a promising target in several types of cancer [8–12].